MRI contrast agent for targeting glioma: Interleukin-13 labeled liposome encapsulating gadolinium-DTPA

Neuro-Oncology

Volumn 18, Issue 5, 2016, Pages 691-699

  Liu, Xiaoli ^a   Madhankumar, Achuthamangalam B ^a   Miller, Patti A ^a   Duck, Kari A ^a   Hafenstein, Susan ^a   Rizk, Elias ^a   Slagle Webb, Becky ^a   Sheehan, Jonas M ^a   Connor, James R ^a   Yang, Qing X ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

blood brain barrier (BBB); glioma; IL 13; liposome; targeted MRI contrast agent

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE MEGLUMINE; INTERLEUKIN 13 LIPOSOME GADOLINIUM PENTETIC ACID; UNCLASSIFIED DRUG; GADOLINIUM PENTETATE; INTERLEUKIN 13; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; SENSITIVITY ANALYSIS; ANIMAL; BRAIN TUMOR; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; PROCEDURES;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; GLIOMA; INTERLEUKIN-13; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MICE;

EID: 84965168293     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov263     Document Type: Article

References (43)

1. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006;24(8): 1253-1265.
2. Nathan C, Varghai D, Flask CA, Oleinick NL, Feyes DK, Dean D. Optional Gadolinium dose level for magnetic resonance imaging (MRI) contrast enhancement of U87-derived tumors in athymic nude rats for the assessment of photodynamic therapy. Proc of SPIE. 2009;7161(2Y):1-10.
3. Fatterpekar GM, Galheigo D, Narayana A, Johnson G, Knopp E. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum-use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol. 2012;198(1):19-26.
4. Vriens D, van Laarhoven HW, van Asten JJ, et al. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J Nucl Med. 2009;50(11):1777-1784.
5. Madsen SJ, Hirschberg H. Site-specific opening of the blood-brain barrier. J Biophotonics. 2010;3(5-6):356-367.
6. Roberts J, Kahle MP, Bix GJ. Perlecan and the blood-brain barrier: beneficial proteolysis? Front Pharmacol. 2012;3(155):1-5.
7. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959-1972.
8. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
9. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1-2):54-61.
10. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660-668.
11. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA. 1996;93(24):14164-14169.
12. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res. 2003;42(5):439-462.
13. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx. 2005;2(1):99-107.
14. Tilcock C, Unger E, Cullis P, MacDougall P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology. 1989; 171(1):77-80.
15. Unger EC, MacDougall P, Cullis P, Tilcock C. Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. Magn Reson Imaging. 1989;7(4):417-423.
16. Unger EC, Winokur T, MacDougall P, et al. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology. 1989; 171(1):81-85.
17. Vartholomeos P, Fruchard M, Ferreira A, Mavroidis C. MRI-guided nanorobotic systems for therapeutic and diagnostic applications. Annu Rev Biomed Eng. 2011;13:157-184.
18. Caput D, Laurent P, Kaghad M, et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J Biol Chem. 1996;271(28): 16921-16926.
19. Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/ testis antigen. Mol Med. 2000;6(5):440-449.
20. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res. 1999;5(5):985-990.
21. Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol. 2000;48(2):103-111.
22. Fillmore HL, Shultz MD, Henderson SC, et al. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. Nanomedicine (Lond). 2011;6(3):449-458.
23. Witusik-Perkowska M, Zakrzewska M, Szybka M, et al. Astrocytomaassociated antigens-IL13Ralpha2, Fra-1, and EphA2 as potential markers to monitor the status of tumour-derived cell cultures in vitro. Cancer Cell Int. 2014;6(3):449-458.
24. Sengupta S, Thaci B, Crawford AC, Sampath P. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int. 2014;2014(1):1-8.
25. DebinskiW,ObiriNI, Powers SK, Pastan I, Puri RK.Human gliomacells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res. 1995;1(11):1253-1258.
26. Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther. 2006;5(12): 3162-3169.
27. Madhankumar AB, Slagle-Webb B, Wang X, et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumormodel. Mol Cancer Ther. 2009;8(3):648-654.
28. Nguyen V, Conyers JM, Zhu D, et al. IL-13Ralpha2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol. 2011;4(6):390-400.
29. Chittiboina P, Heiss JD, Warren KE, Lonser RR. Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr. 2014;13(3):276-282.
30. Debinski W, Miner R, Leland P, Obiri NI, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem. 1996;271(37):22428-22433.
31. Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010;6(5): 421-432.
32. Hernandez-Caselles T, Villalain J, Gomez-Fernandez JC. Stability of liposomes on long term storage. J Pharm Pharmacol. 1990;42(6): 397-400.
33. Corathers SD. Focus on diagnosis: the alkaline phosphatase level: nuances of a familiar test. Pediatr Rev. 2006;27(10):382-384.
34. Allhenn D, Shetab Boushehri MA, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm. 2012;436(1-2):299-310.
35. Ding D, Kanaly CW, Bigner DD, et al. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol. 2010;98(1):1-7.
36. Salomir R, Hokland S, Pedersen M. Magnetic resonance imaging (MRI)-directed focussed [sic] ultrasound. Methods and applications in oncological treatment [Article in Danish]. Ugeskr Laeger. 2005;167(39):3667-3672.
37. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 2007; 121(4):901-907.
38. Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev. 2002;28 (Suppl A): 3-6.
39. Ng K, Zhao L, Liu Y, Mahapatro M. The effects of polyethyleneglycol (PEG)-derived lipid on the activity of target-sensitive immunoliposome. Int J Pharm. 2000;193(2):157-166.
40. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297-315.
41. Perche F, Torchilin VP. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv. 2013;1: 1-32.
42. Bedu-Addo FK, Tang P, Xu Y, Huang L. Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharm Res. 1996;13(5):710-717.
43. Haar PJ, Broaddus WC, Chen ZJ, Fatouros PP, Gillies GT, Corwin FD. Gd-DTPA T1 relaxivity in brain tissue obtained by convection-enhanced delivery, magnetic resonance imaging and emission spectroscopy. Phys Med Biol. 2010;55(12): 3451-3465.